Date: 2014-12-15
Type of information: Nomination
Compound: vice-president
Company: Gilead (USA - CA)
Therapeutic area: Cancer - Oncology - Hepatic diseases - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 15, 2014, Gilead Sciences announced that Philippe C. Bishop, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutics. In this position, Dr. Bishop will report to John McHutchison, MD, Executive Vice President, Clinical Research and will have responsibility for Gilead’s programs in oncology. Dr. Bishop will also join Gilead’s Executive Committee. Dr. Bishop joins Gilead from Genentech, where he has served as Vice President, Product Development, Oncology since 2007. At Genentech, he was responsible for the development of Avastin, contributed to many of the company’s oncology pipeline therapeutics and was a member of the Roche/Genentech joint leadership team. Prior to joining Genentech, Dr. Bishop led efforts to develop cancer therapies at Johnson & Johnson and Sanofi-Aventis. Dr. Bishop also previously held positions at the FDA and the National Institutes of Health (NIH). Dr. Bishop received his undergraduate degree from Loyola Marymount University in Los Angeles and his medical degree from the University of Nevada School of Medicine. He completed training in internal medicine at the University of Washington School of Medicine and a medical oncology fellowship at the National Cancer Institute (NCI).
Financial terms:
Latest news:
Is general: Yes
